The global APOL1 mediated kidney disease market is expected to attain a valuation of USD 3779.9 million in 2023 and is projected to reach USD 5753.9 million by 2033, trailing a CAGR of 4.3% during the forecast period.
The market is anticipated to experience growth during the projected timeframe, primarily due to significant factors such as the escalating burden of focal segmental glomerulosclerosis (FSGS) and a strong emphasis on the development of innovative treatment alternatives.
In an October 2022 article by MedSpace, it was revealed that Focal segmental glomerulosclerosis (FSGS) ranks among the most prevalent causes of primary glomerular disease in adults. When adults undergo kidney biopsy to evaluate proteinuria, approximately 35% of cases are attributed to FSGS. Moreover, African-American patients make up 80% of the subjects affected by this condition.
In a July 2022 publication by the National Library of Medicine, it was reported that focal segmental glomerulosclerosis (FSGS) is a commonly observed contributor to nephrotic syndrome, responsible for 40% of cases in adults and 20% in children. This escalating prevalence of FSGS is projected to propel the growth of the studied market.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 3779.9 million |
| Anticipated Forecast Value (2033) | USD 5753.9 million |
| Projected Growth Rate (2023 to 2033) | CAGR 4.3% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The APOL1 mediated kidney disease market was worth USD 3002.7 million in 2017. It accumulated a market value of USD 3627.7 million in 2022 while growing at a CAGR of 3.9% during the historical period.
According to several influential experts in the field, the APOL1 mediated kidney disease market shows significant promise, but its future path hinges entirely on the widespread availability and accessibility of APOL1 screening, particularly among young adults. While raising awareness about APOL1 genetic variants and their associated diseases is crucial, it is only the initial step toward achieving effective therapies in this domain.
By arranging free APOL1 screening initiatives, pharmaceutical companies can gather authentic data regarding the true prevalence and risk of APOL1 mediated kidney disease. These companies are projected to concentrate their efforts on populations at higher risk for APOL1 kidney diseases, particularly individuals of African descent. This targeted approach aims to streamline the screening and treatment process, saving valuable time.
Collaborative efforts between governments, pharmaceutical companies, and research institutes are being undertaken to promote awareness campaigns. Facilitating easy access to APOL1 diagnostics will create broader opportunities for pharmaceutical players. Once the product is launched, the clinical pipeline potential is expected to be significant in terms of value.
At present, the clinical pipeline for APOL1 mediated kidney disease treatment is limited, with only two pharmaceutical companies actively involved in this area. Vertex Pharmaceuticals Incorporated has its small molecule inhibitor, VX-147, in Phase 2 of clinical trials, while AstraZeneca collaborates with Ionis Pharmaceuticals for APOL1-associated chronic kidney disease, with an investigational molecule currently in Phase 1. The scarcity of treatments in the pipeline creates appealing prospects for further research and development within the market.
The market is projected to be worth USD 5753.9 million by the end of forecast period while exhibiting a CAGR of 4.3%.
Development of Next-gen Targeted Therapies to Propel Market Growth
Prominent biopharmaceutical developers in the clinical stage are directing their efforts toward developing next-generation targeted therapeutics to combat APOL1 mediated kidney diseases, particularly chronic kidney diseases. The potential for addressing unmet needs in this field is attracting both established and emerging biopharmaceutical companies to pursue a targeted therapeutic approach. This emerging trend is anticipated to provide a competitive edge and establish exclusive market dominance on a global scale in the coming years.
The global market for chronic kidney disease drugs is expected to experience substantial growth, driven by the rising number of drug approvals from regulatory authorities. A notable instance of this is the recent announcement by Bayer AG, a pharmaceutical company, on June 30, 2022.
The Chinese National Medical Products Administration (NMPA) granted marketing authorization for Finerenone, which is marketed under the name Kerendia. Kerendia, available in 10 mg or 20 mg dosages, is a non-steroidal, selective mineralocorticoid receptor (MR) antagonist specifically indicated for the treatment of chronic kidney disease (CKD). This regulatory approval exemplifies the positive momentum in the market's expansion.
Principal Consultant
High Cost of Treatment may Restrain Market Expansion
Market growth may face hindrances due to the high cost of dialysis and kidney transplants. Also, the side effects associated with these medications such as loss of appetite, fever, and rashes are expected to hold back market expansion.
North America Driving Growth with Significant CAGR
The North American APOL1 mediated kidney disease market accounted for a revenue share of 85.4% in 2022. The demand outlook for APOL1 mediated kidney disease treatment in the region is expected to grow with a CAGR of 4.1% during the forecast period.
In 2020, the United States market value for symptomatic treatment exceeded USD 2.0 billion and is projected to experience remarkable growth momentum. APOL1 associated kidney diseases are notably prevalent among black Americans, as these mutations have been shown to be inherited within populations of African origin.
According to the United States Census, approximately 13% of the United States population comprises African Americans. Among populations of African origin, the prevalence of APOL1-associated kidney diseases is the highest compared to other regions. Additionally, the prevalence rate of hypertension-attributable kidney disease is 12% among this demographic. Furthermore, the current therapeutic pipeline is primarily focused on launching in the regional market. These factors collectively establish the United States as a prominent player in the APOL1-mediated kidney disease treatment market.
Asia Pacific Driving Growth with a Significant CAGR
The market in Asia Pacific is expected to grow with a significant CAGR of 4.2% during the forecast period. India is expected to dominate the Asia Pacific market and is expected to grow with a CAGR of 4.4% throughout the forecast period.
The growth of the market can be attributed to the rising prevalence of end-stage diseases and significant investments in healthcare by governments in the Asia-Pacific region. Additionally, the APOL 1 mediated kidney disease treatment market in India is expected to hold a leading market share, while the market in China is projected to be a rapidly growing market in the Asia-Pacific region.
India's healthcare sector is experiencing a significant growth rate, and the prevalence of chronic kidney disease is also on the rise due to factors such as increased life expectancy and a sedentary lifestyle. This is expected to drive growth in the chronic kidney disease market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Chronic Kidney Disease to Drive Growth with Significant CAGR
In 2022, the chronic kidney disease segment accounted for a colossal revenue share of 95.07% in the APOL 1 mediated kidney disease therapeutics market. The segment is expected to flourish at a significant CAGR of 5.8% during the forecast period.
Funding allocated for kidney research falls short compared to oncology research, despite the number of individuals diagnosed with kidney disorders each year surpassing those diagnosed with cancer. This disparity is evident in the significant focus on new drug discoveries in the field of oncology, while nephrology research lags behind. By the second quarter of 2019, there was only one late-stage study dedicated to nephrology, while 39 studies were conducted in the field of cancer.
The National Institutes of Health (NIH) allocated funding for cancer research that was ten times greater than the funding for kidney disorders. It is reported that approximately 20 percent of individuals over the age of 60 have chronic kidney disease (CKD). Surprisingly, the pipelines of ten prominent pharmaceutical companies contain fewer than 30 active molecules dedicated to nephrology, whereas the number reaches 1,300 for cancer.
According to the American Society of Nephrology (ASN) Research Advocacy Committee, NIH spending for cancer patients exceeds USD500 per year, while for chronic kidney disease patients it is only USD30. The limited activity in kidney research has significantly impacted the healthcare industry. Several expensive phase III trials in kidney research have failed to achieve improved outcomes, further diminishing interest in the field.
The end-stage renal segment is expected to grow with a CAGR of 2.1% during the forecast period. The growth is attributed to is expected to factors such as a growing number of kidney failure patients and the introduction of advanced products like low-maintenance dialysis equipment and artificial kidneys.
The increasing number of patients, with a 5-7% annual increase, requiring kidney transplants or dialysis for survival is shaping the segment growth. Additionally, the rising incidence of renal failure in developed and developing countries has stimulated the introduction of technologically advanced products in the market.
Start-ups play a crucial role in identifying growth opportunities in various markets, including the APOL1 mediated kidney disease market. Their ability to generate high returns contributes to the expansion of the industry. Start-ups are often more efficient in converting inputs into outputs and are adaptable to unpredictable market conditions. Here are some start-ups expected to drive growth in the APOL1 mediated kidney disease treatment market.
The APOL1 mediated kidney disease market is extremely competitive and consists of various key industry players. These players are heavily investing in manufacturing APOL1 mediated kidney disease.
The key industry players are Vertex Pharmaceuticals Incorporated, Ionis Pharmaceuticals, AstraZeneca, Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Merck & Co., Inc., Sanofi S.A., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Roche Holding AG.
Some recent developments in the market are:
Key industry players leverage organic growth strategies like acquisition, mergers, partnerships, and collaboration to enhance their product portfolio. This is expected to fuel the global APOL1 mediated kidney disease market.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 3779.9 million |
| Market Value in 2033 | USD 5753.9 million |
| Growth Rate | CAGR of 4.3% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | By Indication, By region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa (MEA) |
| Key Countries Profiled | United States of America, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, China, Japan, Malaysia, Singapore, Thailand, South Korea, Australia, New Zealand, UAE, South Africa, Israel, GCC countries |
| Key Companies Profiled | Vertex Pharmaceuticals Incorporated; Ionis Pharmaceuticals; AstraZeneca; Pfizer Inc.; Novartis AG; GlaxoSmithKline plc; Merck & Co., Inc.; Sanofi S.A.; Johnson & Johnson; AbbVie Inc.; Bristol-Myers Squibb Company; Roche Holding AG |
| Customization | Available Upon Request |
The market is valued at USD 3.7 billion in 2023.
Vertex Pharmaceuticals Incorporated, and Ionis Pharmaceuticals are key market players.
The market shall reach USD 5.7 billion in 2033.
The market is forecast to register a CAGR of 4.3% through 2033.
From 2017 to 2022, the market registered a CAGR of 3.9%.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 5.1. Chronic Kidney Disease 5.1.1. Focal segmental glomerulosclerosis (FSGS) 5.1.2. Human immunodeficiency virus (HIV)-associated Nephropathy 5.1.3. Hypertension-associated Kidney Disease 5.2. End-Stage Kidney Disease 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 6.1. North America 6.2. Latin America 6.3. Europe 6.4. Asia Pacific 6.5. Middle East and Africa 7. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Key Countries Market Analysis 13. Market Structure Analysis 14. Competition Analysis 14.1. Pfizer Inc. 14.2. AstraZeneca 14.3. Novartis AG 14.4. GlaxoSmithKline plc 14.5. Merck & Co., Inc. 14.6. Sanofi S.A. 14.7. Johnson & Johnson 14.8. AbbVie Inc. 14.9. Bristol-Myers Squibb Company 14.10. Roche Holding AG 15. Assumptions & Acronyms Used 16. Research Methodology
Explore Healthcare Insights
View Reports
APOL1 Mediated Kidney Disease Market
